LONG-TERM STENT PATENCY RATES IN DIABETIC PATIENTS UNDERGOING PCI

doi:N/A

eISSN: 1994-4624 / ISSN: 1813-176x

International Journal of Molecular Medicine and Advance Sciences

2022, Volume 18, Issue 2 : 31-35

Research Article

LONG-TERM STENT PATENCY RATES IN DIABETIC PATIENTS UNDERGOING PCI

Arif Rahman

Meera Kulkarni

Hassan Al- Zahiri

Department of Cardiovascular Medicine, Eastern Heart Institute, New Delhi, India

Division of Cardiology, Global Medical Center, Singapore

Department of Medical Biostatistics, University of Doha, Qatar

Received

Aug. 18, 2022

Revised

Sept. 29, 2022

Accepted

Nov. 11, 2022

Published

Dec. 21, 2022

Abstract

Diabetes mellitus (DM) is a major risk factor for coronary artery disease (CAD) and reduces long-term stent patency following percutaneous coronary intervention (PCI). This quantitative cohort study evaluates long-term patency rates of drug-eluting stents (DES) versus bare-metal stents (BMS) over a 5-year follow-up among 1,240 diabetic patients undergoing PCI. Results show significantly higher restenosis and target lesion revascularization (TLR) among poorly controlled diabetics (HbA1c ≥ 8.0) and those receiving BMS. DES demonstrated a 5-year patency rate of 81.4%, while BMS showed 53.2%. The study highlights the need for glycemic control and the superiority of next-generation DES in diabetic subgroups.

Keywords

Diabetes mellitus

PCI

Stent patency

Restenosis

Drug-eluting stent

HbA1c

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.

Int. J. Mol. Med. Adv. Sci. open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.

Recommended Articles

“Outcomes of TAVR vs SAVR Among High-Risk Patients”

39-42

Impact of Dual Antiplatelet Therapy Duration on Post-PCI Outcomes

Arif Hasan,

Maria V. Lopez,

Kunal S. Mehra

11-14

Percutaneous Balloon Angioplasty as First-Line Therapy in Low-Income Patients

Sameer Rahman,

Elena Rodriguez,

Michael Turner